Compare iShares MSCI Taiwan ETF (EWT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Smith & Nephew plc — how do they compare? iShares MSCI Taiwan ETF trades at $114.31 (market cap $12.74B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: iShares MSCI Taiwan ETF and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Smith & Nephew plc for 121 Days on average.
| EWT | SNN | |
|---|---|---|
Market Cap | $12.74B | $11.10B |
Volume | 8,470,920 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $37.17 |
52-Week Low | $60.03 | $26.42 |
Typical Hold Time | 52 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT trades at $114.31, down 1.66% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong exposure to Taiwan's semiconductor sector, particularly TSMC, driving AI-related growth potential. Recent news highlights Taiwan's $20 billion investment in US AI infrastructure and institutional buying interest from Bank of America.
Outlook remains positive due to Taiwan's central role in AI chip manufacturing, though geopolitical risks with China pose significant headwinds. Valuation appears reasonable for tech-focused exposure, but investors must weigh growth potential against regional political uncertainty.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
